首页> 美国卫生研究院文献>Neuropsychopharmacology >Frontal Theta Cordance Predicts 6-Month Antidepressant Response to Subcallosal Cingulate Deep Brain Stimulation for Treatment-Resistant Depression: A Pilot Study
【2h】

Frontal Theta Cordance Predicts 6-Month Antidepressant Response to Subcallosal Cingulate Deep Brain Stimulation for Treatment-Resistant Depression: A Pilot Study

机译:额叶Theta Cordance预测6个月对call门下扣带回深脑刺激治疗抗抑郁性药物的抗抑郁反应:一项初步研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Deep brain stimulation (DBS) of subcallosal cingulate white matter (SCC) may be an effective approach for treatment-resistant depression (TRD) that otherwise fails to respond to more conventional therapies, but DBS is invasive, costly, and has potential for adverse effects. Therefore, it is important to identify potential biomarkers for predicting antidepressant response before intervention. Resting-state EEG was recorded from 12 TRD patients at pre-treatment baseline, after 4 weeks SCC DBS, and after 24 weeks SCC DBS. Lower frontal theta cordance (FTC) at baseline (and higher FTC after 4 weeks) predicted lower depression severity scores after 24 weeks. Greater FTC increases (baseline–4 weeks) predicted greater decreases in depression severity scores subsequently (4–24 weeks) and over the course of the study (baseline–24 weeks). Predictive relationships were topographically specific to theta cordance for frontal electrodes. Thus, results from this pilot study suggest that baseline FTC and changes early in treatment each have utility as biomarkers for predicting 6-month clinical response to SCC DBS for TRD.
机译:call骨扣带回扣状白质(SCC)的深部脑刺激(DBS)可能是抗药性抑郁症(TRD)的有效方法,否则该抗药性抑郁症无法对更常规的疗法产生反应,但DBS具有侵入性,昂贵且具有潜在的不良反应。因此,重要的是在干预之前确定潜在的生物标志物,以预测抗抑郁药的反应。在治疗前基线,SCC DBS 4周后和SCC DBS 24周后记录了12位TRD患者的静息状态EEG。基线时较低的额叶thetacordance(FTC)(4周后较高的FTC)预测24周后抑郁症严重程度评分较低。 FTC的增加(基线至4周)越大,则预示抑郁症严重程度评分随后(4至24周)和在研究过程中(基线至24周)的降低就越大。预测关系在地形上特定于额电极的thetacorance。因此,该初步研究的结果表明,基线FTC和治疗早期的变化均可用作预测6个月对SCC DBS TRD的临床反应的生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号